Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway.

The recent discovery of the angiotensin II (Ang II)-breakdown enzyme, angiotensin I converting enzyme (ACE) 2, suggests the importance of Ang II degradation in hypertension. The present study explored the signaling mechanism by which ACE2 is regulated under hypertensive conditions. Real-time PCR and immunohistochemistry showed that ACE2 mRNA and protein expression levels were high, whereas ACE expression levels were moderate in both normal kidney and heart. In contrast, patients with hypertension showed marked ACE up-regulation and ACE2 down-regulation in both hypertensive cardiopathy and, particularly, hypertensive nephropathy. The inhibition of ACE2 expression was shown to be associated with ACE up-regulation and activation of extracellular regulated (ERK)1/2 and p38 mitogen-activated protein (MAP) kinases. In vitro, Ang II was able to up-regulate ACE and down-regulate ACE2 in human kidney tubular cells, which were blocked by an angiotensin II (AT)1 receptor antagonist (losartan), but not by an AT2 receptor blocker (PD123319). Furthermore, blockade of ERK1/2 or p38 MAP kinases by either specific inhibitors or a dominant-negative adenovirus was able to abolish Ang II-induced ACE2 down-regulation in human kidney tubular cells. In conclusion, Ang II is able to up-regulate ACE and down-regulate ACE2 expression levels under hypertensive conditions both in vivo and in vitro. The AT1 receptor-mediated ERK/p38 MAP kinase signaling pathway may be a key mechanism by which Ang II down-regulates ACE2 expression, implicating an ACE/ACE2 imbalance in hypertensive cardiovascular and renal damage.

[1]  H. Kobori,et al.  The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease , 2007, Pharmacological Reviews.

[2]  A. Hamaguchi,et al.  Activation of glomerular mitogen-activated protein kinases in angiotensin II-mediated hypertension. , 1998, Journal of the American Society of Nephrology : JASN.

[3]  L. Truong,et al.  Advanced Glycation End Products Activate a Chymase-Dependent Angiotensin II–Generating Pathway in Diabetic Complications , 2006, Circulation.

[4]  C. Ferrario,et al.  Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. , 1998, Hypertension.

[5]  D. Diz,et al.  Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.

[6]  T. Ogihara,et al.  Deletion of Angiotensin-Converting Enzyme 2 Accelerates Pressure Overload–Induced Cardiac Dysfunction by Increasing Local Angiotensin II , 2006, Hypertension.

[7]  C. Folberth,et al.  Hypertension transmitted by kidneys from stroke-prone spontaneously hypertensive rats. , 1989, The American journal of physiology.

[8]  M. Crackower,et al.  Angiotensin-converting enzyme 2 is an essential regulator of heart function , 2002, Nature.

[9]  D. Batlle,et al.  ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. , 2007, Kidney international.

[10]  M. Huentelman,et al.  Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats , 2005, Experimental physiology.

[11]  D. Averill,et al.  Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. , 2005, Kidney international.

[12]  R. Khokha,et al.  Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. , 2007, Cardiovascular research.

[13]  L. Truong,et al.  Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. , 2003, Journal of the American Society of Nephrology : JASN.

[14]  J. Penninger,et al.  Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. , 2007, The American journal of pathology.

[15]  H. Kobori,et al.  AT1 Receptor Mediated Augmentation of Intrarenal Angiotensinogen in Angiotensin II-Dependent Hypertension , 2004, Hypertension.

[16]  M. Chappell,et al.  Does the angiotensin-converting enzyme (ACE)/ACE2 balance contribute to the fate of angiotensin peptides in programmed hypertension? , 2005, HYPERTENSION.

[17]  N. Perico,et al.  The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. , 2005, Kidney international. Supplement.

[18]  L. Navar,et al.  Angiotensin II type 1 receptor-mediated augmentation of renal interstitial fluid angiotensin II in angiotensin II-induced hypertension , 2003, Journal of Hypertension.

[19]  C. Ferrario,et al.  Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. , 2005, American journal of physiology. Heart and circulatory physiology.

[20]  C. Ferrario,et al.  Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. , 2006, American journal of physiology. Cell physiology.

[21]  M. Burnier,et al.  Blockade of the renin–angiotensin–aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes , 2006, Journal of hypertension.

[22]  H. van Goor,et al.  Renal ACE2 expression in human kidney disease , 2004, The Journal of pathology.

[23]  B. Brenner,et al.  Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  Kerstin Amann,et al.  Nephron number in patients with primary hypertension. , 2003, The New England journal of medicine.

[25]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[26]  M. Crackower,et al.  Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis , 2006, The American Journal of Pathology.

[27]  C. Lau,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension: United States National Health and Nutrition Examination Survey 2001–2002 , 2006, Journal of clinical hypertension.

[28]  M. Donoghue,et al.  Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. , 2006, The Journal of clinical investigation.

[29]  A C Guyton,et al.  Kidneys and fluids in pressure regulation. Small volume but large pressure changes. , 1992, Hypertension.

[30]  H. Drexler,et al.  Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. , 1994, The Journal of clinical investigation.

[31]  V. Dzau,et al.  The renin-angiotensin-aldosterone system: a specific target for hypertension management. , 1999, American journal of hypertension.

[32]  S. Doggrell,et al.  Vascular chymase: pathophysiological role and therapeutic potential of inhibition. , 2004, Cardiovascular research.

[33]  I. Fleming.  Signaling by the Angiotensin-Converting Enzyme , 2006, Circulation research.

[34]  O. Patschan,et al.  Kidneys from normotensive donors lower blood pressure in young transplanted spontaneously hypertensive rats. , 1997, The American journal of physiology.

[35]  V. Campese.  Salt sensitivity in hypertension. Renal and cardiovascular implications. , 1994, Hypertension.